Y-mAbs Therapeutics, Inc.

YMAB · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$30-$21-$96-$55
Dep. & Amort.$1$1$1$1
Deferred Tax$0$0$0$2
Stock-Based Comp.$15$14$26$19
Change in WC-$4-$20-$10-$7
Other Non-Cash$3-$1$4-$62
Operating Cash Flow-$16-$27-$76-$103
Investing Activities
PP&E Inv.$0$0$0-$1
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$62
Investing Cash Flow$0$0$0$61
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$4$0$0$108
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$1
Financing Cash Flow$4$0$0$108
Forex Effect$0$0$0$0
Net Chg. in Cash-$11-$27-$76$67
Supplemental Information
Beg. Cash$79$106$182$115
End Cash$67$79$106$182
Free Cash Flow-$16-$27-$76-$104
Y-mAbs Therapeutics, Inc. (YMAB) Financial Statements & Key Stats | AlphaPilot